118 related articles for article (PubMed ID: 38751950)
1. Acu-URO17 is a highly sensitive and specific bladder cancer biomarker.
Guo L; Cid A; Cucci J; Kunkel B; Defeis L; Matthews M
BJUI Compass; 2024 May; 5(5):497-501. PubMed ID: 38751950
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of URO17® to improve non-invasive detection of bladder cancer.
Porten SP; Wang EY; Vohra P; Carroll PR; Jahanfard S; Kim NW
Urol Oncol; 2024 Jun; 42(6):176.e21-176.e28. PubMed ID: 38553264
[TBL] [Abstract][Full Text] [Related]
3. The role of URO17® in diagnosis and follow up of bladder cancer patients.
Ibrahim M; Rabinowitz J; Hilbert R; Ghose A; Agarwal S; Swamy R; Bulut I; Guttierrez M; Buali E; Nassar E; Jhavar P; Al-Hashimi F; Vasdev N
BMC Urol; 2024 Feb; 24(1):34. PubMed ID: 38336681
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
7. [Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder].
Asali MG; Kaneti J; Manor E
Harefuah; 2007 Dec; 146(12):914-9, 1000. PubMed ID: 18254439
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of FISH for detecting upper tract urothelial carcinoma in voided urine specimens.
Yu Q; Li Y; Li G; Li T; Zeng H; Yang Z; Wang D
Oncol Lett; 2016 Jul; 12(1):183-188. PubMed ID: 27347122
[TBL] [Abstract][Full Text] [Related]
9. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
10. UroVysion fluorescence in situ hybridization (UroVysion FISH) assay for detection of bladder cancer in voided urine of Turkish patients: a preliminary study.
Dodurga Y; Avcı CB; Yılmaz S; Nazlı O; Coğulu O; Cankaya T; Gündüz C
Contemp Oncol (Pozn); 2013; 17(2):156-60. PubMed ID: 23788983
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of urine cytology in detecting high-grade urothelial carcinoma in patients with neoplastic urinary bladder diverticula: A major cancer center experience.
Alhamar M; Al-Ahmadie HA; Feratovic R; Lin O
Cancer Cytopathol; 2024 Mar; 132(3):144-151. PubMed ID: 38054371
[TBL] [Abstract][Full Text] [Related]
12. Negative predictive value and sensitivity of urine cytology prior to implementation of The Paris System for Reporting Urinary Cytology.
McIntire PJ; Khan R; Hussain H; Pambuccian SE; Wojcik EM; Barkan GA
Cancer Cytopathol; 2019 Feb; 127(2):125-131. PubMed ID: 30668891
[TBL] [Abstract][Full Text] [Related]
13. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
[TBL] [Abstract][Full Text] [Related]
14. UBC®Rapid Is Sensitive in Detecting High-Grade Bladder Urothelial Carcinoma and Carcinoma in situ in Asian Population.
Zang Z; Kesavan NR; Esuvaranathan K
Urol Int; 2023; 107(1):29-34. PubMed ID: 36273445
[TBL] [Abstract][Full Text] [Related]
15. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology.
Odisho AY; Berry AB; Ahmad AE; Cooperberg MR; Carroll PR; Konety BR
Eur Urol; 2013 May; 63(5):936-40. PubMed ID: 22521093
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma.
Shang D; Liu Y; Xu X; Chen Z; Wang D
Cancer Cell Int; 2021 Sep; 21(1):465. PubMed ID: 34488763
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of fluorescence
Lin T; Liu Z; Liu L; Yang L; Han P; Zhang P; Wei Q
Oncol Lett; 2017 May; 13(5):3928-3934. PubMed ID: 28529600
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
[TBL] [Abstract][Full Text] [Related]
20. The positive predictive value of "suspicious for high-grade urothelial carcinoma" in urinary tract cytology specimens: A single-institution study of 665 cases.
Joudi AM; Pambuccian SE; Wojcik EM; Barkan GA
Cancer Cytopathol; 2016 Nov; 124(11):811-819. PubMed ID: 27508949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
